featured-image

designer491 Shares of Verastem ( NASDAQ: VSTM ) jumped 20% in post-market trading Thursday after the biotech company released positive interim data from a Phase 1/2 study of its drugs avutometinib and defactinib in the treatment of metastatic pancreatic cancer. Verastem is testing avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel as a first-line treatment for metastatic pancreatic cancer. The study showed that 83% of patients achieved a confirmed partial response in cohort 1, the most mature dose level.

It added that one incident of dose-limiting toxicity was observed, but the dose level was subsequently cleared after the enrollment of more patients, according to the company . The company added that a follow-up of patients in the other cohorts is ongoing to determine the recommended Phase 2 dose. Verastem said the study results will be presented on June 1 at the annual meeting of the American Society of Clinical Oncology.



More on Verastem Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial information for Verastem.

Back to Health Page